期刊文献+

转移性结直肠癌anti-EGFR治疗耐药分子标志物的研究进展 被引量:3

下载PDF
导出
摘要 治疗转移性结直肠癌(m CRC)的表皮生长因子受体(EGFR)单克隆抗体(anti-EGFR)靶向药物包括西妥昔单抗和帕尼单抗。靶向药物治疗m CRC达到了增加疗效和延长生存期的效果,但是部分患者对该类药物存在不敏感或耐药现象,其机制尚未完全揭示。伴随着EGFR信号通路研究的深入,越来越多的anti-EGFR治疗的耐药分子标志物被发现。KRAS突变是目前仅知的具有真正临床意义的anti-EGFR单抗治疗m CRC的独立耐药预测因素。此外EGFR基因拷贝数的改变,NRAS、BRAF、PIK3CA等基因突变,PTEN蛋白的失活,EGFR配体AREG/EREG的mRNA表达水平及miRNA Let-7 LCS6的多态性等都可能与anti-EGFR单抗治疗m CRC耐药相关。通过回顾近年来报道的西妥昔单抗和帕尼单抗治疗m CRC耐药相关的分子标志物,对其研究进展进行综述。
出处 《医药导报》 CAS 2015年第1期77-81,共5页 Herald of Medicine
基金 浙江省公益性技术应用研究计划(2014C33157) 浙江省医药卫生科技计划(2014KYA225)
  • 相关文献

参考文献31

  • 1VECCHIONE L, JACOBS B, NORMANNO N, et al. EGFR- targeted therapy [ J]. Exp Cell Res,2011,317 (19) :2765- 2771.
  • 2孙杰,姜丽娜,潘赛英.西妥昔单抗联合卡培他滨与奥沙利铂治疗晚期结直肠癌20例[J].医药导报,2012,31(1):17-19. 被引量:13
  • 3CIARDIELLO F,TORTORA G. EGFR antagonists in cancer treatment [ J]. N Engl J Med,2008,358 ( 11 ) : 1160-1174.
  • 4刘媛,刘东伯,龙国贤,胡国清.吉非替尼和依维莫司对EGFR-TKI耐药鼻咽癌细胞的作用[J].医药导报,2014,33(1):43-48. 被引量:4
  • 5GIAMPIERI R, SCARTOZZI M, DEL P M, et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation [ J ]. Crit Rev Oncol Hematol,2013,88 (2) :272-283.
  • 6MORONI M, VERONESE S, BENVENUTI S, et al. Gene copy number for epidermal growth factor receptor(EGFR) and clinical response to antiEGFR treatment in colorectal cancer:a cohort study [ J ]. Lancet Oncol, 2005,6 ( 5 ) : 279-286.
  • 7LAURENT-PUIG P, CAYRE A, MANCEAU G, et al. Ana- lysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer [ J ]. J Clin Oncol, 2009,27 ( 35 ) : 5924 -5930.
  • 8LI Y H, WANG F, SHEN L, et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients [ J ]. Clin Cancer Res, 2011,17 (2) :382-390.
  • 9BOKEMEYER C, VAN CUTSEM E, ROUGIER P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials [ J ]. Eur J Cancer, 2012,48 ( 10 ) : 1466 - 1475.
  • 10BOKEMEYER C, BONDARENKO I, MAKHSON A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer [ J ]. J Clin Oncol, 2009,27 (5) : 663-671.

二级参考文献48

  • 1孙燕,石远凯.内科肿瘤学[M].北京:人民卫生出版社,2007:785-788.
  • 2KOHNE C H, FOLPRECHT G, GOLDBERG R M, et al. Chemotherapy in elderly patients with colorectal cancer [ J ]. Oncologist,2008,13 (4) : 390-402.
  • 3MOOSMANN N, HEINEMANN V. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer[ J ]. Clin Colorectal Cancer, 2008,7 (2) : 110-117.
  • 4BORNER M, KOEBERLE D, VON MOOS R, et al. Ading cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer:-a randomized phase II trim of the swiss group for clinical cancer research SAKK [ J ]. Ann Oncol, 2008, 19 ( 7 ): 1288-1292.
  • 5CARTWRIGHT T, KUEFLER P, COHN A, et al. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as therapy for patients with advanced and/or metastatic colorectal cancer [ J ]. Clin Colorectal Cancer, 2008,7 (6) : 390-397.
  • 6TOL J, KOOPMAN M, RODENBURG C J, et al. A rando- mized phase III study on capecitabine oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer,the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity[ J]. Ann Oncol,2008,19 (4) :734-738.
  • 7VAN CUTSEM E, HENNING-KOHNE C, HITRE E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer [ J]. N Engl J Med,2009,360 (14) :1408-1417.
  • 8BOKEMEYER C, BONDARENKO L, MAKHSON A, eta|. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer [ J ]. J Clin 0ncol,2009,27 (5) : 663-671.
  • 9Adelstein BA, Dobbins TA, Harris CA, et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer, 2011,47 : 1343-1354.
  • 10Cao Y, Liao C, Tan A, et al. Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner: meta-analysis of six randomized trials. Colorectal Dis, 2010, 12:16-23.

共引文献20

同被引文献27

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部